PortalPublikationenEarly response assessment in patients with multiple myeloma ...

Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results

Standard

Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. / Fenchel, Michael; Konaktchieva, Marina; Weisel, Katja; Kraus, Sabina; Brodoefel, Harald; Claussen, Claus D; Horger, Marius.

in: EUR RADIOL, Jahrgang 20, Nr. 12, 12.2010, S. 2899-906.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fenchel, M, Konaktchieva, M, Weisel, K, Kraus, S, Brodoefel, H, Claussen, CD & Horger, M 2010, 'Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results', EUR RADIOL, Jg. 20, Nr. 12, S. 2899-906. https://doi.org/10.1007/s00330-010-1870-z

APA

Fenchel, M., Konaktchieva, M., Weisel, K., Kraus, S., Brodoefel, H., Claussen, C. D., & Horger, M. (2010). Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. EUR RADIOL, 20(12), 2899-906. https://doi.org/10.1007/s00330-010-1870-z

Vancouver

Fenchel M, Konaktchieva M, Weisel K, Kraus S, Brodoefel H, Claussen CD et al. Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. EUR RADIOL. 2010 Dez;20(12):2899-906. https://doi.org/10.1007/s00330-010-1870-z

Bibtex

@article{7e43bb55216f412b9cd4d324aaaac33b,
title = "Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results",
abstract = "OBJECTIVE: To determine if arterial-spin-labelling (ASL) MRI can reliably detect early response to anti-angiogenic therapy in patients with multiple myeloma by comparison with clinical/haematological response.METHODS: Nineteen consecutive patients (10 men; mean age 63.5 ± 9.1 years) were included in the present study. Inclusion criteria were diagnosis of stage III multiple myeloma and clinical indication for therapeutical administration of bortezomib or lenalidomide. We performed MRI on 3.0T MR in the baseline setting, 3 weeks after onset of therapy and after 8 weeks. Clinical responses were determined on the basis of international uniform response criteria in correlation with haematological parameters and medium-term patient outcome. MRI studies were performed after approval by the local institutional review board.RESULTS: Fifteen patients responded to anti-myeloma therapy; 4/19 patients were non-responders to therapy. Mean tumour perfusion assessed by ASL-MRI in a reference lesion was 220.7 ± 132.5 ml min(-1) 100 g(-1) at baseline, and decreased to 125.7 ± 86.3 (134.5 ± 150.9) ml min(-1) 100 g(-1) 3 (8) weeks after onset of therapy (P < 0.02). The mean decrease in paraproteinaemia at week 3 (8) was 52.3 ± 47.7% (58.2 ± 58.7%), whereas β2-microglobulinaemia decreased by 20.3 ± 53.1% (23.3 ± 57.0%). Correlation of ASL perfusion with outcome was significant (P = 0.0037).CONCLUSION: ASL tumour perfusion measurements are a valuable surrogate parameter for early assessment of response to novel anti-angiogenic therapy.",
keywords = "Aged, Angiogenesis Inhibitors, Boronic Acids, Bortezomib, Female, Humans, Lenalidomide, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Myeloma, Pilot Projects, Pyrazines, Reproducibility of Results, Sensitivity and Specificity, Spin Labels, Thalidomide, Treatment Outcome, Journal Article",
author = "Michael Fenchel and Marina Konaktchieva and Katja Weisel and Sabina Kraus and Harald Brodoefel and Claussen, {Claus D} and Marius Horger",
year = "2010",
month = dec,
doi = "10.1007/s00330-010-1870-z",
language = "English",
volume = "20",
pages = "2899--906",
journal = "EUR RADIOL",
issn = "0938-7994",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results

AU - Fenchel, Michael

AU - Konaktchieva, Marina

AU - Weisel, Katja

AU - Kraus, Sabina

AU - Brodoefel, Harald

AU - Claussen, Claus D

AU - Horger, Marius

PY - 2010/12

Y1 - 2010/12

N2 - OBJECTIVE: To determine if arterial-spin-labelling (ASL) MRI can reliably detect early response to anti-angiogenic therapy in patients with multiple myeloma by comparison with clinical/haematological response.METHODS: Nineteen consecutive patients (10 men; mean age 63.5 ± 9.1 years) were included in the present study. Inclusion criteria were diagnosis of stage III multiple myeloma and clinical indication for therapeutical administration of bortezomib or lenalidomide. We performed MRI on 3.0T MR in the baseline setting, 3 weeks after onset of therapy and after 8 weeks. Clinical responses were determined on the basis of international uniform response criteria in correlation with haematological parameters and medium-term patient outcome. MRI studies were performed after approval by the local institutional review board.RESULTS: Fifteen patients responded to anti-myeloma therapy; 4/19 patients were non-responders to therapy. Mean tumour perfusion assessed by ASL-MRI in a reference lesion was 220.7 ± 132.5 ml min(-1) 100 g(-1) at baseline, and decreased to 125.7 ± 86.3 (134.5 ± 150.9) ml min(-1) 100 g(-1) 3 (8) weeks after onset of therapy (P < 0.02). The mean decrease in paraproteinaemia at week 3 (8) was 52.3 ± 47.7% (58.2 ± 58.7%), whereas β2-microglobulinaemia decreased by 20.3 ± 53.1% (23.3 ± 57.0%). Correlation of ASL perfusion with outcome was significant (P = 0.0037).CONCLUSION: ASL tumour perfusion measurements are a valuable surrogate parameter for early assessment of response to novel anti-angiogenic therapy.

AB - OBJECTIVE: To determine if arterial-spin-labelling (ASL) MRI can reliably detect early response to anti-angiogenic therapy in patients with multiple myeloma by comparison with clinical/haematological response.METHODS: Nineteen consecutive patients (10 men; mean age 63.5 ± 9.1 years) were included in the present study. Inclusion criteria were diagnosis of stage III multiple myeloma and clinical indication for therapeutical administration of bortezomib or lenalidomide. We performed MRI on 3.0T MR in the baseline setting, 3 weeks after onset of therapy and after 8 weeks. Clinical responses were determined on the basis of international uniform response criteria in correlation with haematological parameters and medium-term patient outcome. MRI studies were performed after approval by the local institutional review board.RESULTS: Fifteen patients responded to anti-myeloma therapy; 4/19 patients were non-responders to therapy. Mean tumour perfusion assessed by ASL-MRI in a reference lesion was 220.7 ± 132.5 ml min(-1) 100 g(-1) at baseline, and decreased to 125.7 ± 86.3 (134.5 ± 150.9) ml min(-1) 100 g(-1) 3 (8) weeks after onset of therapy (P < 0.02). The mean decrease in paraproteinaemia at week 3 (8) was 52.3 ± 47.7% (58.2 ± 58.7%), whereas β2-microglobulinaemia decreased by 20.3 ± 53.1% (23.3 ± 57.0%). Correlation of ASL perfusion with outcome was significant (P = 0.0037).CONCLUSION: ASL tumour perfusion measurements are a valuable surrogate parameter for early assessment of response to novel anti-angiogenic therapy.

KW - Aged

KW - Angiogenesis Inhibitors

KW - Boronic Acids

KW - Bortezomib

KW - Female

KW - Humans

KW - Lenalidomide

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Pilot Projects

KW - Pyrazines

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Spin Labels

KW - Thalidomide

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1007/s00330-010-1870-z

DO - 10.1007/s00330-010-1870-z

M3 - SCORING: Journal article

C2 - 20589379

VL - 20

SP - 2899

EP - 2906

JO - EUR RADIOL

JF - EUR RADIOL

SN - 0938-7994

IS - 12

ER -